Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities

  • Asian J Androl. 2003 Mar;5(1):15-8.
Z C Xin  1 ,  E K Kim ,  C S Lin ,  W J Liu ,  L Tian ,  Y M Yuan ,  J Fu
Affiliations
  • 1. Department of Urology, the 1st Hospital, Peking University, 8 Xishiku Street, Xicheng District, Beijing 100034, China. [email protected]
PMID: 12646997
Abstract

Aim: To clarify the mechanism of the therapeutic action of icariin on erectile dysfunction (ED).

Methods: PDE5 was isolated from the human platelet and PDE4 from the rat liver tissue using the FPLC system (Pharmacia, Milton Keynes, UK) and the Mono Q column. The inhibitory effects of icariin on PDE5 and PDE4 activities were investigated by the two-step radioisotope procedure with [(3)H]-cGMP/[(3)H]-cAMP. Papaverine served as the control drug.

Results: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities. The IC(50) of Icariin and papaverine on PDE5 were 0.432 micromol/L and 0.680 micromol/L, respectively and those on PDE4, 73.50 micromol/L and 3.07 micromol/L, respectively. The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively.

Conclusion: Icariin is a cGMP-specific PDE5 Inhibitor that may be developed into an oral effective agent for the treatment of ED.

Products